Abstract
Due to their high prevalence, non-alcoholic fatty liver disease (NAFLD), insulin resistance (IR) and hepatitis C virus (HCV) infection are bound to cohabit. However, the relationship between these 3 entities is complex and multilayered. HCV, particularly genotype 3, may induce a “viral” steatosis, morphologically indistinguishable from the steatosis of NAFLD but with different implications and prognosis. On the other hand, epidemiological and experimental data show that patients with HCV have a higher risk of developing IR and, in susceptible individuals, type 2 diabetes (T2D). In patients with HCV, T2D increases fibrosis progression rate, increases the incidence of HCC, worsens liver-related outcomes and worsens response to interferon-α based therapy. We conclude by discussing a possible increased incidence of cardiovascular events in HCV patients.
Keywords: Fibrosis, hepatitis C virus, non-alcoholic fatty liver disease, steatosis.
Graphical Abstract
Reviews on Recent Clinical Trials
Title:Insulin Resistance, Non-alcoholic Fatty Liver Disease and Hepatitis C Virus Infection
Volume: 9 Issue: 3
Author(s): Nicolas Goossens and Francesco Negro
Affiliation:
Keywords: Fibrosis, hepatitis C virus, non-alcoholic fatty liver disease, steatosis.
Abstract: Due to their high prevalence, non-alcoholic fatty liver disease (NAFLD), insulin resistance (IR) and hepatitis C virus (HCV) infection are bound to cohabit. However, the relationship between these 3 entities is complex and multilayered. HCV, particularly genotype 3, may induce a “viral” steatosis, morphologically indistinguishable from the steatosis of NAFLD but with different implications and prognosis. On the other hand, epidemiological and experimental data show that patients with HCV have a higher risk of developing IR and, in susceptible individuals, type 2 diabetes (T2D). In patients with HCV, T2D increases fibrosis progression rate, increases the incidence of HCC, worsens liver-related outcomes and worsens response to interferon-α based therapy. We conclude by discussing a possible increased incidence of cardiovascular events in HCV patients.
Export Options
About this article
Cite this article as:
Goossens Nicolas and Negro Francesco, Insulin Resistance, Non-alcoholic Fatty Liver Disease and Hepatitis C Virus Infection, Reviews on Recent Clinical Trials 2014; 9 (3) . https://dx.doi.org/10.2174/1574887109666141216101939
DOI https://dx.doi.org/10.2174/1574887109666141216101939 |
Print ISSN 1574-8871 |
Publisher Name Bentham Science Publisher |
Online ISSN 1876-1038 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
A Randomized Trial of Short-term Treatment with Folic Acid to Reduce the
Oxidative Stress of Patients with Chronic Kidney Disease
Current Drug Metabolism The Challenges of Blood Pressure Control in Dialysis Patients
Recent Advances in Cardiovascular Drug Discovery (Discontinued) Editorial [ Diseases of the Kidney: Molecular Mechanisms and Current Therapy Executive Editor: Stephen I-Hong Hsu ]
Current Molecular Medicine Research Progress in Predicting DNA Methylation Modifications and the Relation with Human Diseases
Current Medicinal Chemistry Asymmetric Dimethylarginine: Clinical Significance and Novel Therapeutic Approaches
Current Medicinal Chemistry Diagnosis of Renal Diseases Based on Machine Learning Methods Using Ultrasound Images
Current Medical Imaging Human Islet Transplantation: Current Status and Future Direction
Micro and Nanosystems Targeting mTOR Signaling in Type 2 Diabetes Mellitus and Diabetes Complications
Current Drug Targets Thiazoles and Thiazolidinones as Antioxidants
Current Medicinal Chemistry Diabetes and Its Complications: Therapies Available, Anticipated and Aspired
Current Diabetes Reviews Pathophysiology of Diabetic Dyslipidaemia
Current Vascular Pharmacology The Involvement of Growth Hormone (GH), Insulin-Like Growth Factors (IGFs) and Vascular Endothelial Growth Factor (VEGF) in Diabetic Kidney Disease
Current Pharmaceutical Design Meet the Editorial Board Member
CNS & Neurological Disorders - Drug Targets CCL2-CCR2 Signaling in Disease Pathogenesis
Endocrine, Metabolic & Immune Disorders - Drug Targets Effect of Nigella Sativa and Allium Sativum Coadminstered with Simvastatin in Dyslipidemia Patients: A Prospective, Randomized, Double-Blind Trial
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Antioxidant Capacities of Flavones and Benefits in Oxidative-Stress Related Diseases
Current Topics in Medicinal Chemistry Recent Studies on Neural Tube Defects in Embryos of Diabetic Pregnancy: An Overview
Current Medicinal Chemistry Gender Differences in the Treatment of Ischemic Heart Disease
Current Pharmaceutical Design Targeting Chromatin Remodeling to Prevent Cardiovascular Disease in Diabetes
Current Pharmaceutical Biotechnology Glucose Sensors Based on Core@Shell Magnetic Nanomaterials and Their Application in Diabetes Management: A Review
Current Pharmaceutical Design